Webinar – Overcoming the challenges of plasmid DNA in AAV manufacturing
November 30th, 2022 at 11am EST | 4pm GMT | 5pm CET
AAV manufacturing and other types of advanced therapy production are experiencing challenges associated with their plasmid DNA supply. This includes slow or delayed production and poor DNA quality (owing to unstable or difficult sequences), impacting their ability to meet drug development timelines and regulatory demands.
In this webinar, the featured speakers will address the challenges of plasmid DNA in AAV manufacturing and present data and supportive case studies which introduce an alternative to plasmid DNA — an enzymatic, antibiotic-free DNA vector called doggybone DNA (dbDNA™).
Register to learn how doggybone DNA can eliminate many issues around complex or unstable sequences in AAV production, alongside improved speed to manufacture, safety and scalability.
Dr. Lisa Caproni, Head of Vaccine Therapy, Touchlight
Dr. Leszek Lisowski, Unit Head, Children’s Medical Research Institute, University of Sydney
Who Should Attend?
Companies working on genetic medicine and key decision makers for process development or new technology evaluation for:
Job roles include:
- Gene therapy professionals
- Scientists working within viral vector manufacturing
- Process Development Scientists
- VPs and Leaders of Scientific Operations
- CEO, CSO in biotech
- CMC Leaders
- Research Scientists
- Product Managers
What You Will Learn
- Discover an alternative to plasmid DNA — an enzymatic, antibiotic-free DNA vector
- Learn how doggybone DNA can eliminate many of the current issues associated with plasmid DNA and accelerate development timelines
- Hear about case studies and data featuring doggybone DNA applied to AAV